

Hyphens and Cytokine PharmaSciences announce commercialization agreement of obstetric product in Southeast Asia

SINGAPORE (April 28, 2009) – Hyphens Marketing & Technical Services Pte Ltd (“Hyphens”) and Cytokine PharmaSciences, Inc (“CPSI”) announced today that the two companies have entered into an exclusive license and supply agreement (the “Agreement”) to commercialize CPSI’s Propess®, a vaginal insert for cervical ripening and induction of labor, in Singapore, Malaysia, the Philippines and Vietnam (the “Territories”).

The Agreement grants Hyphens exclusive sales and marketing rights to Propess® in the Territories while CPSI’s wholly owned subsidiary, Controlled Therapeutics (Scotland) Ltd. will be responsible for the manufacturing and supply of the product. Besides playing a commercial role, Hyphens will also be responsible for obtaining regulatory approvals of Propess® in the Territories. Financial terms were not disclosed.

“We strongly believe that Propess® will provide an efficacious, safe and cost-effective option to physicians, making it the choice agent for cervical ripening in our region”, said Mr. Lim See Wah, Managing Director of Hyphens. He added, “This collaboration will also bolster our presence in the women’s health space while allowing us to continue serving the obstetricians and gynecologists communities.”

Dennis Willson, CPSI’s President and CEO stated: “We are enormously pleased to have a partner of the caliber of Hyphens and are confident that they will make Propess the standard of care for cervical ripening and induction of labor in their Territories”. He added, “We look forward to a long and prosperous relationship with them, not just for Propess but for other products in the field of women’s health.”

About Propess®

Propess® vaginal insert, is a sustained-release formulation of dinoprostone, a synthetic prostaglandin E2 used when there is a medical need for cervical ripening, i.e., preparing the cervix for labor. The insert comes in a knitted polyester retrieval system, allowing quick and easy removal at the appropriate time (e.g., following the onset of labor). The insert is approved in over 50 countries around the world including the US, EU, Canada, China, India, Mexico, Australia and New Zealand.

About Hyphens Marketing & Technical Services Pte Ltd

Hyphens is a specialty pharmaceutical company focused on sales and marketing of innovative human health care products in Southeast Asia. With regional headquarters in Singapore and local offices in Cambodia, Indonesia, Malaysia, the Philippines and Vietnam, Hyphens has successfully launched numerous key products. The Company’s core therapeutic areas are Allergy & Otolaryngology, Gastroenterology, Obstetrics & Gynecology, Ophthalmology and Radiology. Hyphens currently partners with a host

of companies from Australia, Europe and the USA. For more information, kindly visit www.hyphens.com.sg

About Cytokine PharmaSciences, Inc.

Cytokine is a biopharmaceutical company located in King of Prussia (near Philadelphia), Pennsylvania. The company developed and manufactures Cervidil®/Propess® at Controlled Therapeutics (Scotland) Ltd, in Scotland. The product is used in the obstetrics field for cervical ripening in the induction of labor. CPSI is focused on the use of polymers for the delivery of drugs to the vagina or buccal cavity, as well as the development of novel targets and therapeutic agents for the treatment of inflammation, autoimmune diseases and cancer. For more information, kindly visit www.cytokinepharmasciences.com

Contact:

Lim See Wah, Managing Director
Hyphens Marketing & Technical Services Pte Ltd
+65 6338 8551
Email: limsw@hyphens.com.sg

Dennis F. Willson, CEO
Cytokine PharmaSciences, Inc.
(+1) 610-687-1776 x211
Email: dwillson@cytokinepharmasciences.com

###